Inhibikase Therapeutics, Inc.IKTNASDAQ
Loading
Total Costs & Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+41.4%
5Y CAGR+71.1%
Studio
Year-over-Year Change

Total of all costs and expenses

3Y CAGR
+41.4%/yr
vs +71.3%/yr prior
5Y CAGR
+71.1%/yr
Recent deceleration
Acceleration
-29.8pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
14.7x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$51.62M+80.6%
2024$28.59M+40.5%
2023$20.35M+11.5%
2022$18.25M+2.2%
2021$17.87M+408.0%
2020$3.52M-48.4%
2019$6.82M+221.4%
2018$2.12M-13.9%
2017$2.47M+56.0%
2016$1.58M-